PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Nov 24, 2020

bybhenderson

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Marietta, Ohio, November 24, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results analysing the benefit of PKX-001 on human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to an experimental model of blindness due to...Read more

Oct 30, 2020

byprotokinetixp

AAGP® | biotechnology | biotechnology investments | dry-eye | market opportunity

Biotech Investing: How to Pick a Winner

The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times, investors have been burned by biotech stocks that burn fast and bright before completely flaming out. What these investors are looking for is not just...Read more

Oct 02, 2020

byprotokinetixp

Benefits of AAGP® | Islet Cell Transplants

AAGP®'s role in islet cell transplants

Sep 22, 2020

byprotokinetixp

dry-eye | Ocular inflammation

Dry Eye Disease: Investor Presentation

Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our dry eye disease investors deck to learn how Protokinetix is creating biotechnology that can help change the future of how we treat dry eye disease.

Sep 21, 2020

byprotokinetixp

Seeking improved treatments for dry eye disease

A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including nearly twice as many women as men. There is no single cause for eye dryness. It can be temporary or chronic and result from a...Read more

Sep 15, 2020

bybhenderson

ProtoKinetix AAGP® Restores Vision in Blind Test Subjects

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively achieved. Based on these results Dr. Kevin Gregory-Evans shortly submitting a paper for publication in a peer reviewed journal. In vivo tests demonstrated that...Read more

Aug 27, 2020

bybhenderson

Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada

Marietta, Ohio, August 27, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that Dr. James Shapiro has received approval from Health Canada and the University of Alberta Ethics Committee for the ammendments to the clinical trial protocol. This phase of the clinical trials, based on safety data received from...Read more

Aug 21, 2020

byprotokinetixp

Invest in the potential of AAGP® for type-1 diabetes

While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been shown to have protective properties that could help with the causes and consequences of this difficult disease. If you are interested in getting involved in...Read more

Aug 14, 2020

bybhenderson

ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing

Marietta, Ohio, August 14, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that due the results that AAGP® has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing. “In our in vitro model of rat...Read more

Jul 20, 2020

byprotokinetixp

How world-renowned researchers are exploring a potential Type 1 diabetes cure

For anyone living with Type 1 diabetes, there is no doubt it is a challenging illness. Type 1 diabetes occurs at no fault of the patient, but unfortunately, there is no known cause or cure. ProtoKinetix researchers are actively exploring the potential for our anti-aging glycopeptide, AAGP®, to make better treatments possible. Continue reading to learn...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.